Questions Cases 2017 - Operaciones
Questions Cases 2017 - Operaciones
Questions Cases 2017 - Operaciones
Description
Barilla SpA, an Italian manufacturer that sells to its retailers largely through third-party
distributors, experienced widely fluctuating demand patterns from its distributors
during the late 1980s. This case describes a proposal to address the problem by
implementing a continuous replenishment program, under which the responsibility for
determining shipment quantities to the distributors would shift from the distributors
to Barilla. Describes support and resistance within Barilla's different functional areas
and within the distributors Barilla approached with the proposal.
QUESTIONS:
1.Diagnose the underlying causes of the difficulties that the JITD program was
created to solve. What are the benefits and drawbacks of this program?
3.As one Barillas customers, what would your response to JITD be? Why?
4.In the environment in which Barilla operated in 1990, do you belive JITD (or a
similar kind of program) would be feasible? Effective? If so, which cutomers
would you target next? How would you convince them that JITD program was
worth trying? If not, what alternatives would you suggest to combat some of
the difficulties that Barillas operating system face?
QUESTIONS
1. Consider the experiences that you (or your Friends or members of your family)
have had in buying a car; compare these to the experience of buying a
computer online (if you have never done this, go to Dells website
www.dell.com- and explorehow online computer buying works). What do you
think explains the differences?
2. What challenges does Dell derive from virtual integration? How important are
these advantages in the auto business?
3. What challanges doesFord face that are not also faced by Dells? How should
Ford deal with these chalanges?
4. If you were Teri Takai, what would you recommend to senior executives?To
what degree should Ford emulate Dells business model?
QUESTIONS:
1. How is Fruitvale Branch doing?
2. What are the causes of these problems?
3. Can you identify the problems in the way Manzana is calculating turnaround
time in Exhibit 3 ?
4. If you were Bill Pippen, what would you recommend that Fruitvale do?
QUESTIONS:
1. Why did Tektronix implement ERP in stages? How should a Company decide
between implementing in stages or going big-bang?
2. How did Tektronix manage the risks of ERP implementation?
3. What is your overall assessment of the Tektronix ERP Project?
TOYOTA
Description
On May 1, 1992, Doug Friesen, manager of assembly for Toyota's Georgetown,
Kentucky, plant, faces a problem with the seats installed in the plant's sole product--
Camrys. A growing number of cars are sitting off-line with defective seats or are
missing them entirely. This situation is one of several causes of recent overtime, yet
neither the reason for the problem nor a solution is readily apparent. As the plant is an
exemplar of Toyota's famed production system (TPS), Friesen is determined that, if
possible, the situation will be resolved using TPS principles and tools. Students are
asked to suggest what action(s) Friesen should take and to analyze whether
Georgetown's current handling of the seat problem fits within the TPS philosophy.
QUESTIONS:
1. As Doug Friesen, what would you do to adress the seat problem? Where would
you focus your attention and solution efforts?
2. What options exist? What would you recommend? Why?
3. What is the real problem facing Doug Friesen?
MILLIENNIUM
Description
Focuses on Millennium's strategy to grow and revolutionize drug development through
the use of new technologies such as genomics. Describes how Millennium
Pharmaceuticals--a fast-growing biotechnology firm in Cambridge, MA--has used
strategic alliances to finance the development of technology platforms based on the
latest breakthroughs in genomics.
QUESTIONS:
As the firm considers developing pharmaceutical drugs itself, they face a number of
challenges:
1) Can they revolutionize drug development by making it more predictable, faster, and
less costly?
2) How should they select their alliances such that they move closer to becoming a
pharmaceutical firm and still attract the funding needed for their strategy?
3) How can they continue to grow rapidly and attract and retain some of the best
minds in the pharmaceutical industry?